Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02252887
Title Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Gemcitabine + Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.